PAC Partners Equity Research released its latest research and valuation report on Anatara Lifesciences (ANR). The report provided a SPEC BUY rating and a 12-month price target of $0.90 per share
http://crweworld.com/australia/trendingnow/press-releases/1164792/-anatara-lifesciences-ltd-asxanr-pac-partners-equity-research-report-
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.007(63.6%) |
Mkt cap ! $4.058M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 2.0¢ | 1.2¢ | $620.0K | 35.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1788227 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 1315621 | 2 |
View Market Depth
| Last trade - 14.11pm 10/09/2025 (20 minute delay) ? |
| ANR (ASX) Chart |